Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Algenpantucel-L in pancreatic cancer
NCT01836432Phase 3Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- May 2013
- Primary completion
- Jul 2016
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of algenpantucel-L in pancreatic cancer (PC), sponsored by Lumos Pharma, Inc.. Started May 2013; status: terminated.
02
Drugs
algenpantucel-L
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01836432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01836432.